LawCash Links

Recommended

A lawsuit seeking class action status has been filed in Cook County against the Alden Group, a Chicago nursing home, argues that the hours of care provided to each resident falls short of the minimum demanded under state rules.

Kahn Gauthier Swick is investigating possible legal actions against drug giant Pfizer, Inc., the manufacturer of the prescription drug Neurontin (gabapentin), to recover for harm suffered by patients who have been prescribed Neurontin.

Numerous class actions have been filed against nonprofit hospitals in Illinois, Minnesota, Ohio, Texas, Georgia, Alabama, Florida and Tennessee, on behalf of uninsured patients who allege that the hospitals do not honor their promise of charity care as defined in their tax-exempt status. The suits claim that the hospitals are charging uninsured patients "sticker" price while insurance companies negotiate large discounts for the same services provided to those with medical coverage, violating the hospitals’ tax-exempt status.

The parties have reached a settlement apparently valued at $5,850,000 in an action filed against the Insurance of America Agency, Inc., the National Business Association, Inc., the American National Insurance Company, Inc., and the American National Life Insurance Company of Texas on behalf of all persons (1) who obtained certificates of insurance from American National Life Insurance Company of Texas, Inc., or American National Insurance Company, that were the subject of a trust agreement in which those companies were the administrators for the National Business Association insurance program after October 12, 1996, or (2) who were over eighteen as of July 1, 2003, and were insured under certificates containing a co-pay and wellness benefit rider offered by American National Life Insurance Company of Texas when notices issued in their state of residence that the rider was to be deleted. Persons who have not received notification, but are eligible to take part in the action should contact class counsel as soon as possible.

Kahn Gauthier Swick is investigating possible legal actions against Eli Lilly and Company, the manufacturer of the prescription drug Zyprexa (olanzapine), on behalf of patients prescribed Zyprexa who have developed diabetes, hyperglycemia (elevated blood sugar), and other blood sugar disorders as a result of the drug. A recent $690 million dollar settlement has been announced for certain Zyprexa claimants.

Several class actions have been filed against pharmaceuticals and healthcare supply wholesaler D&K Healthcare Resources, Inc. (Nasdaq:DKHR) and certain of its officers and directors by stockholders who purchased the company's common stock between April 23, 2001, and September 16, 2002. The actions claim that the defendants violated federal securities laws by issuing a series of material misrepresentations to the market over this time period, thereby artificially inflating the price of the company's securities.

IT'S FREE